ASX:NOX
Market Cap:
Price Delay ~20min
Interactive 2020
Annual Report

Media

21-Aug-2020

Global biotech news service, BioWorld, in its Other News To Note, covered Noxopharm's reporting (11 Aug 2020) that, " Independent research published in European Urology Oncology showed the combination of 177Lu-PSMA-617 radioligand therapy and Veyonda (idronoxil), its sphingosine-1-phosphate inhibitor, was safe and effective, with median overall survival (OS) of 17.1 months in late-stage prostate cancer patients who exhausted standard treatment options. Median OS in a study conducted in a comparable population who received standard chemotherapy was 4.5 months." 

Click here to read more.

19-Aug-2020

US Life Science website, Clinical Research News, said Noxopharm had announced new research showing Veyonda® cancer survival rates in a peer-reviewed publication, European Urology Oncology,  the first official publication of the European Association of Urology that is fully devoted to the study of genitourinary cancer.

Click here to read more.

18-Aug-2020

Pharmaceutical news digital site, FirstWord Pharma, continued coverage on Noxopharm's lead drug candidate, Veyonda®'s trials in late -stage prostate cancer.

Click here to read more.

18-Aug-2020

PharmaVOICE.com provided the news release, "Noxopharm Announces New Research Showing Veyonda® Cancer Survival Rates" which reported that the Australian clinical-stage drug development company announced the publication of the first manuscript of the LuPIN trial in the journal, European Urology Oncology. This journal is the first official publication of the European Association of Urology that is fully devoted to the study of genitourinary cancer.

Click here to read more.

18-Aug-2020

Life Sciences digital hub, BioSpace, reported on Noxopharm's announcement (11 August 2020) regarding the details of the peer-reviewed publication of key LuPIN (Phase 2) study data in its ongoing late-stage prostate cancer trial.

Click here to read more.

29-Jul-2020

US website Clinical Research News reported on Noxopharm's pre-clinical announcement concerning idronoxil's ability to convert 'cold' cancer tumours to 'hot' ones in the laboratory.

Click here to read more.

23-Jul-2020

BioWorld notes in its section Other News to Note for July 23,2020, "Noxopharm Ltd reported preclinical data from two independent research groups confirming that idronoxil, the active ingredient in the company's immuno-oncology drug candidate, and sphingosine-1-phosphate inhibitor, Veyonda, activate cancer-fighting immune cells and then enable their entry into microtumors. Noxopharm said other preclinical and clinical data, together with the new research data, leads the company to believe it is close to claiming the first drug capable of converting tumors from cold to hot across multiple cancer types in a well-tolerated way"

Click here to read more.

23-Jul-2020

US online forum BioSpace reports Noxopharm's announcement, " Noxopharm Reports Idronoxil Achieves Major Industry Goal of Converting 'Cold' Tumors to 'Hot'.

Click here to read more.

2-Jul-2020

US publication Clinical Research News: the Industry Updates section mentions Noxopharm's planned COVID-19 trial using Veyonda®.

Click here to read more.